deltatrials
Completed PHASE4 INTERVENTIONAL 1-arm NCT00867932

Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paroxysmal Nocturnal Hemoglobinuria (PNH)

An Open-Label Multi-Center Study of Eculizumab in Children and Adolescents With a Diagnosis of Paroxysmal Nocturnal Hemoglobinuria

Sponsor: Alexion Pharmaceuticals, Inc.

Conditions Hemoglobinuria, Paroxysmal
Interventions Eculizumab
Updated 12 times since 2017 Last updated: Oct 3, 2018 Started: Oct 2, 2009 Primary completion: May 12, 2011 Completion: May 12, 2011
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00867932, this PHASE4 trial focuses on Hemoglobinuria, Paroxysmal and remains completed. Sponsored by Alexion Pharmaceuticals, Inc., it has been updated 12 times since 2009, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshotCompleted~Apr 2017 – ~Jun 2018 · 14 months · monthly snapshotCompleted~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshotCompleted~Nov 2018 – ~Jan 2021 · 26 months · monthly snapshotCompleted~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshotCompleted~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotCompleted~Jan 2023 – ~Apr 2023 · 3 months · monthly snapshotCompleted~Apr 2023 – ~Dec 2023 · 8 months · monthly snapshotCompleted~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

12 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  3. Dec 2023 — Jul 2024 [monthly]

    Completed PHASE4

  4. Apr 2023 — Dec 2023 [monthly]

    Completed PHASE4

  5. Jan 2023 — Apr 2023 [monthly]

    Completed PHASE4

▶ Show 7 earlier versions

  1. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE4

  2. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE4

  3. Nov 2018 — Jan 2021 [monthly]

    Completed PHASE4

  4. Jun 2018 — Nov 2018 [monthly]

    Completed PHASE4

  5. Apr 2017 — Jun 2018 [monthly]

    Completed PHASE4

    Phase: PHASE1_PHASE2 → PHASE4

  6. Feb 2017 — Apr 2017 [monthly]

    Completed PHASE1_PHASE2

  7. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Oct 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Alexion Pharmaceuticals, Inc.
Data source: Alexion Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations